GRI Bio, Inc.
Close on Oct 19, 2026
- Market cap
- $2.62M
- P/E (TTM)
- –
- Dividend yield
- –
About GRI Bio
Pharmaceutical Preparations, SIC 2834
GRI Bio is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses. Its pipeline concentrates on inflammatory, fibrotic, and autoimmune disorders by regulating Natural Killer T (NKT) cell activity. The company's lead product candidate, GRI-0621, is an oral inhibitor of type 1 invariant NKT cells being developed to treat severe fibrotic lung diseases, primarily idiopathic pulmonary fibrosis. Its portfolio also includes GRI-0803, an oral activator of type 2 diverse NKT cells aimed at treating autoimmune conditions such as systemic lupus erythematosus, along with a proprietary compound library. Because its pipeline is in clinical and preclinical development stages, the company serves patient populations in clinical trials rather than commercial end customers.
The company operates without internal commercial manufacturing infrastructure, contracting with third-party manufacturers to supply product candidates for its research and clinical studies. Its clinical studies include multicenter and multinational trials. The company's headquarters are not stated in the text.
Summary of the business section of GRI Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- GRI Bio, Inc.
- Headquarters
- La Jolla, CA
- Address
- 2223 Avenida De La Playa, Suite 208 92037
- Phone
- (619) 400-1171
- Employees
- 4, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- WithumSmith+Brown, PC, San Francisco, California
Stock & identifiers
- Ticker
- GRI
- Exchange
- Nasdaq
- IPO date
- Feb 11, 2021
- Shares outstanding
- 2M, Aug 13, 2026
- Public float
- $1.50M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-28 reverse, Jan 26, 2026; 1-for-17 reverse, Feb 24, 2025; 1-for-13 reverse, Jun 18, 2024; 1-for-7 reverse, Jan 30, 2024; 1-for-7 reverse, Jan 29, 2024; 1-for-30 reverse, Apr 24, 2023; 1-for-30 reverse, Apr 21, 2023
- SEC CIK
- 1824293
- CUSIP
- 3622AW502
- ISIN
- US3622AW5029
- EIN
- 82-4369909
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Walter Marc Hertz | Chief Executive Officer, Director | 385,510 |
| Leanne Kelly | Chief Financial Officer | 6,250 |
| Vipin Chaturvedi | Chief Scientific Officer | 172,189 |
| Roelof Rongen | Director | – |
| David Charles Baker | Director | 7,843 |
| David Leslie Szekeres | Director | – |
| Camilla V. Simpson | Director | – |
Employees
Headcount reported in annual reports
“As of January 30, 2026 we had four employees, of which three were full-time employees and one was part-time.”
Corporate history
Events identified from SEC filings